Healthcare Losers: Cytokinetics (NASDAQ:CYTK), Achillion Pharmaceuticals (NASDAQ:ACHN), Pharmacyclics (NASDAQ:PCYC), Organovo Holdings Inc (NYSEMKT:ONVO)

Cytokinetics, Inc. (NASDAQ:CYTK) announced disappointing top-line results from its BENEFIT-ALS midstage study involving tirasemtiv. Tirasemtiv did not meet its primary efficacy endpoint of delivering a mean change from baseline in the ALS functional rating scale. Cytokinetics, Inc. (NASDAQ:CYTK) stock performance was -64.67% in last session and finished the day at $4.59. Traded volume was 17.26million shares in the last session and the average volume of … Continue reading Healthcare Losers: Cytokinetics (NASDAQ:CYTK), Achillion Pharmaceuticals (NASDAQ:ACHN), Pharmacyclics (NASDAQ:PCYC), Organovo Holdings Inc (NYSEMKT:ONVO)

NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

Some drugs that have gained approval this year so far include AstraZeneca’s Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) (to treat neurogenic orthostatic hypotension), BioMarin’s Vimizim (Morquio A syndrome) and Vanda Pharma’s Hetlioz. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -5.75% in last session and finished the day at $4.92. Traded volume was 3.02million shares in … Continue reading NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)